75000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 75010 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 75020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 75030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 75040 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Organization and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Collaboration and License Agreements link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - California Institute for Regenerative Medicine Award link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Convertible Preferred Stock and Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Collaboration and License Agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Organization and Summary of Significant Accounting Policies - (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Organization and Summary of Significant Accounting Policies - Schedule of reconciliation of cash, cash equivalents, and restricted cash (Details) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Organization and Summary of Significant Accounting Policies - Schedule of Basic and diluted net loss per share attributable to stockholders (Details) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Organization and Summary of Significant Accounting Policies - Schedule of weighted-average outstanding shares of potentially dilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Collaboration and License Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Collaboration and License Agreements (Details 1) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Collaboration and License Agreements (Details 2) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - California Institute For Regenerative Medicine Award (Details) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Investments (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Investments (Details 1) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Fair Value Measurements (Details 1) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Leases (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Leases (Details 1) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Leases (Details 2) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Leases - Schedule of Future undiscounted minimum lease payments (Details) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Leases - Schedule of Future undiscounted minimum lease payments (Details) 2 link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Additional information) (Details) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Stock option activity under all equity and stock option plans (Details) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Restricted stock unit activity under all equity and stock option plans (Details) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Stock based compensation for all stock awards (Details) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Weighted average assumptions used in the Black-Scholes option pricing model (Details) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Reconciliation of Consolidated Stockholders' Equity Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Segment Reporting (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Segment Reporting - Schedule of Segment Profit or Loss, Including Segment Expenses (Details) link:presentationLink link:calculationLink link:definitionLink Commercial option exercise Commercial option exercise [Member] Commercial option exercise [Member] Vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Research and development expense Other Research and Development Expense Upfront Cash Payment Upfront Cash Payment Upfront cash payment Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Private placement of pre-funded warrants Private Placement of Pre Funded Warrants Private placement of pre Funded warrants Preferred Stock, Shares Issued, Total Preferred stock, issued shares Preferred Stock, Shares Issued Balance Sheet Location Statement of Financial Position Location, Balance [Domain] Balance at the beginning of the period Balance at the end of the period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Supplemental schedule of noncash investing and financing activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Weighted-average pre-funded warrants Weighted-average pre-funded warrants Weighted-average pre-funded warrants Plan Name [Axis] Equity [Abstract] Entity Current Reporting Status Entity Current Reporting Status Operating expenses: Operating Expenses [Abstract] Less: Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Weighted-Average Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] California Institute For Regenerative Medicine [Member] California institute for regenerative medicine . California Institute for Regenerative Medicine Common stock, authorized shares Common Stock, Shares Authorized Investments Investment, Policy [Policy Text Block] Product and Service Product and Service [Axis] Fair Value by Liability Class Fair Value by Liability Class [Domain] Document Fiscal Period Focus Document Fiscal Period Focus Aggregate research and development fees payments receivable Collaborative Arrangement Aggregate Payments Receivable Collaborative arrangement aggregate payments receivable. Entity Shell Company Entity Shell Company Accrued other Other Accrued Liabilities, Current Short-Term Investments [Member] Short-term Investments Cash and Cash Equivalents, at Carrying Value, Ending Balance Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and Cash Equivalent Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Denominator: Option exercise payment Option Exercise Payment Option exercise payment. Common Stock, Shares, Issued, Total Common stock issued Common Stock, Shares, Issued Asset Class Asset Class [Domain] Statement [Table] Statement [Table] Right-of-use assets and lease liabilities, net Increase Decrease In Right Of Use Assets And Lease Liabilities Net Increase decrease in right-of-use assets and lease liabilities, net. Expected volatility Fair Value Assumptions Expected Volatility Rate1 Fair Value Assumptions Expected Volatility Rate 1. Restricted cash Restricted Cash, Noncurrent Accured Interest on investments Interest Receivable Statement [Line Items] Statement [Line Items] Warrant [Member] Entity Filer Category Entity Filer Category Number of Restricted Stock Units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Total liabilities and stockholders’ equity Liabilities and Equity Payables and Accruals [Abstract] Candidate two. Candidate 2 Candidate Two [Member] Ono Letter Agreement Ono Letter Agreement [Member] Ono Letter Agreement. Money market funds Cash and Cash Equivalents, Fair Value Disclosure Share issue price (in dollars per share) Shares Issued, Price Per Share Collaboration And License Agreements Disclosure [Abstract] No definition available. Short-term leases term excluded from calculation of ROU and lease liabilities Short Term Leases Term Excluded From Calculation Of Right Of Use Of Assets And Lease Liabilities Short-term leases term excluded from calculation of right of use of assets and lease liabilities. Interest income Investment Income, Interest Interest income Stock Price Appreciation Milestones Liabilities Non Current Stock price appreciation milestones, non current portion. Stock price appreciation milestones Cash, Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Transaction price of the agreement Transaction Price Of Agreement Transaction price of agreement. Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Basic and Diluted Net Loss per Share Attributable to Stockholders Non Rule 10b51 Arr Modified Flag Non Rule 10b51 Arr Modified Flag Non-Rule 10b5-1 Arrangement Modified Expected ressarch services period. Expected Ressarch Services Period Expected ressarch services period Common Stock Options Share-Based Payment Arrangement [Member] Earnings Per Share, Basic Earnings Per Share, Basic, Total Net loss per common share, basic Net loss per share, basic Amended MSK License Amended M S K License [Member] Amended MSK license member. Balance at the beginning of the period Balance at the end of the period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Going Concern Assessment Liquidity Policy [Text Block] Liquidity. Total current liabilities Liabilities, Current Current Liability Accounts receivable Accounts receivable Increase (Decrease) in Accounts Receivable Adjustments to reconcile net loss to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] 2031 Lessee, Operating Lease, Liability, to be Paid, Year Five Summary of Changes in the Fair Value of the Company's Level 3 Enterprise Fair Value Milestone Payment Liability Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Public Equity Offering Public Equity Offerings [Policy Text Block] Public Equity Offerings [Policy Text Block] Percentage of number of employee reduced Restructuring and Related Cost, Number of Positions Eliminated, Period Percent Stockholders’ equity: Equity, Attributable to Parent [Abstract] Entity Small Business Entity Small Business Retained Earnings (Accumulated Deficit), Ending Balance Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Total Accumulated deficit Retained Earnings (Accumulated Deficit) Sublicense Consideration Represents an Asset Under ASC, Other Assets and Deferred Costs Sublicense Consideration Represents an Asset Under ASC, Other Assets and Deferred Costs Sublicense consideration represents an asset under ASC, other assets and deferred costs Preferred Stock [Member] Preferred Stock Cancelled Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Proceeds from Issuance Initial Public Offering Gross proceeds from the public offering Proceeds from public offering of common stock, net of issuance costs Common stock per share Sale of Stock, Price Per Share Convertible Preferred Stock And Stockholders Equity Disclosure [Abstract] Convertible preferred stock and stockholders' equity. Milestone payment under Deferred revenue Milestone Payment Under Deferred Revenue Milestone Payment Under Deferred Revenue Organization and summary of significant accounting policies Organization, Consolidation and Presentation of Financial Statements [Abstract] Janssen Biotech Inc Janssen Biotech Inc [Member] Janssen Biotech Inc. Leases [Abstract] Weighted Average Number of Shares Outstanding, Diluted, Adjustment, Total Weighted Average Number of Shares Outstanding, Diluted, Adjustment Weighted-average common shares outstanding Lessee Lease Description [Line Items] Lessee, Lease, Description [Line Items] Amendment Flag Amendment Flag Product and Service Product and Service [Domain] Proceeds from Sale, Maturity and Collection of Investments, Total Maturities of investments Proceeds from Sale, Maturity and Collection of Investments Number of shares to be purchased Class of Warrant or Right, Number of Securities Called by Warrants or Rights Award agreement executed date Award Agreement Executed Date Award agreement executed date. Net Loss per Common Share Earnings Per Share, Policy [Policy Text Block] Liabilities and Stockholders’ Equity Liabilities and Equity [Abstract] non-cash expenses non-cash expenses Entity Address, Postal Zip Code Entity Address, Postal Zip Code Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Net cash used in operating activities Common Stock [Member] Common Stock Granted Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Personnel Costs Personnel Costs Personnel costs 2029 Lessee, Operating Lease, Liability, to be Paid, Year Three Investment maturity date range. Investment Maturity Date Range Maturity (in years) Schedule Of Available For Sale Securities [Line Items] Debt Securities, Available-for-Sale [Line Items] Entity Address, Address Line One Entity Address, Address Line One Schedule of Weighted-Average Assumptions Used to Determine The Fair Value of Employee and Nonemployee Stock Option Grants Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Earnings Per Share [Abstract] Net loss per share, basic and diluted Common stock multiple Common Stock Multiple Common stock multiple. November2016 Placement [Member] November 2016 Placement November 2016 placement. Balance Sheet Location Statement of Financial Position Location, Balance [Axis] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Unrealized loss on available-for-sale securities, net Class of Warrant or Right Class of Warrant or Right [Axis] Document Type Document Type Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Short-Term Investments [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Entity Central Index Key Entity Central Index Key Summary of Investments Debt Securities, Available-for-Sale [Table Text Block] Risks and Uncertainties Risks And Uncertainties Policy [Text Block] Risks and uncertainties. Net change in cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Ten-trading day trailing average common stock price Trailing Stock Price Per Share Trailing stock price per share. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive securities (in shares) Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Proceeds from issuance of pre-funded warrants, net of issuance costs Proceeds from Issuance of Warrants Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Debt Securities, Available-for-sale, Total Estimated Fair Value Debt Securities, Available-for-Sale Investment Contra research and development expenses Contra Research and Development Expenses Contra research and development expenses Summary of Changes in Stockholders' Equity Schedule of Stockholders Equity [Table Text Block] Milestone Three Milestone Three [Member] Milestone Three Member. Exercised Exercise of stock options, net of issuance costs (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Total current accrued expenses Accrued expenses Accrued Liabilities, Current Issuance of common stock upon vesting of restricted stock units Stock Issued During Period, Value, Restricted Stock Award, Gross Current Fiscal Year End Date Current Fiscal Year End Date Janssen Agreement Janssen Agreement [Member] Janssen agreement. Restricted Cash and Cash Equivalents, Noncurrent, Total Restricted cash Restricted Cash and Cash Equivalent, Noncurrent Document Quarterly Report Document Quarterly Report Private Placement of Pre-Funded Warrants [Policy Text Block] Private Placement of Pre-Funded Warrants [Policy Text Block] Private Placement of Pre-Funded Warrants Entity Address, State or Province Entity Address, State or Province Balance at the beginning of the period Balance at the end of the period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Preferred Stock, Shares Outstanding, Ending Balance Preferred Stock, Shares Outstanding, Beginning Balance Preferred stock, outstanding shares Preferred Stock, Shares Outstanding Unrealised Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Class of Warrant or Right Class of Warrant or Right [Domain] Clinical Programs, Expense Clinical Programs, Expense Clinical programs Amortization of sublicense consideration Amortization Of Sub License Consideration Amortization of sub license consideration. General And Administrative Expense Other General and Administrative Expense Schedule of Allocation of Stock-Based Compensation for All Stock Awards Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Collaborative arrangement annual payments receivable recorded as deferred revenue Collaborative Arrangement Annual Payments Receivable Recorded Under Deferred Revenue Collaborative arrangement annual payments receivable recorded under deferred revenue. Exercise of stock options, net of issuance costs Stock Issued During Period, Value, Stock Options Exercised Comprehensive Income, Policy [Policy Text Block] Comprehensive Loss Collaboration and License Agreements Collaborative Arrangement Disclosure [Text Block] Antidilutive Securities Antidilutive Securities [Axis] Type of Revenue [Extensible List] Revenue, Product and Service [Extensible Enumeration] Related Party Transaction Related Party Transaction [Axis] Accumulated Other Comprehensive Gain (Loss) AOCI Attributable to Parent [Member] Finite-Lived Intangible Assets, Major Class Name Finite-Lived Intangible Assets, Major Class Name [Domain] Weighted-average assumptions to determine fair value of stock options Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Cash and Cash Equivalents Cash and Cash Equivalents [Domain] Stock Price Appreciation Milestones Stock Price Appreciation Milestones Policy [Text Block] Stock price appreciation milestones. Lessee, operating lease, option to extend Lessee, Operating Lease, Option to Extend Preferred stock, $0.001 par value; authorized shares - 5,000,000 Class A Convertible Preferred shares issued and outstanding - 2,755,086 at March 31, 2026 and December 31, 2025 Preferred Stock, Value, Issued, Ending Balance Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Total Preferred Stock, Value, Issued Minimum Minimum [Member] Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Financial Instrument Financial Instrument [Axis] Current assets: Assets, Current [Abstract] FT Eight One Nine [Member] FT Eight One Nine [Member] FT819 [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Financial liabilities: Liabilities, Fair Value Disclosure [Abstract] Segment Reporting [Abstract] Schedule of Assets Measured at Fair Value on Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Current liabilities: Liabilities, Current [Abstract] Terms of conversion Preferred Stock, Convertible, Terms Accrued clinical trial related costs Accrued Clinical Trial Related Costs Current Accrued clinical trial related costs current. Shares, Outstanding Beginning Balance (in shares) Ending Balance (in shares) Sublease Income Sublease income Accounts Receivable, after Allowance for Credit Loss, Current, Total Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Other Income Renewal term Lessee, Operating Lease, Renewal Term Commitments and contingencies Commitments and Contingencies Leases Lessee, Leases [Policy Text Block] Balance at the beginning of the period Balance at the end of the period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Terms of exercise Warrants Exercise Terms Description Warrants exercise terms description. General and Administrative Expense [Member] General and Administrative Total lease liability Total lease liability Total lease liability Total lease liability Operating Lease, Liability Employee And Non Employee Stock Option Employee And Non Employee Stock Option [Member] Represents an arrangement whereby both an employee and a non-employee is entitled to receive in the future, subject to vesting and other restrictions, certain number of shares in the entity at a specified price, as defined in the agreement. Determine the estimated fair value of the enterprise value milestone payments Fair Value Measurement Inputs and Valuation Techniques [Abstract] Purchase price of prefunded warrants Purchase Price Of Prefunded Warrants Purchase price of prefunded warrants. Lessee Lease Description [Table] Lessee, Lease, Description [Table] Johnson Johnson Innovation J J D C Inc Johnson Johnson Innovation J J D C Inc [Member] Johnson & Johnson Innovation-JJDC, Inc. Purchases of property and equipment in accounts payable Capital Expenditures Incurred but Not yet Paid Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Non-refundable upfront payments recorded as deferred revenue Upfront Non Refundable Non Creditable Payment Receivable Upfront non-refundable non-creditable payment receivable. CIRM award liability, noncurrent. C I R M Award Liability Noncurrent CIRM award liability, net of current portion Estimated term (in years) Fair Value Assumptions Expected Term1 Fair Value Assumptions Expected Term 1. Weighted-average common shares used to compute basic net loss per share Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Basic, Total Employee termination related costs Other Employee-related Liabilities Segment Reporting, Expense Information Used by CODM, Description Segment Reporting Expense Information Employee Retention Credit Employee Retention Credit Policy Employee Retention Credit Policy Proceeds from Issuance of Private Placement Proceeds from issuance of private placement Private placement of pre-funded warrants, net of issuance costs APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Total stockholders’ equity Equity, Attributable to Parent Beginning Balance Ending Balance Payments to Acquire Investments, Total Purchases of investments Payments to Acquire Investments Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Unaudited Interim Financial Information Basis of Accounting, Policy [Policy Text Block] Lessee, operating lease, existence of option to extend Lessee, Operating Lease, Existence of Option to Extend [true false] Use of Estimates Use of Estimates, Policy [Policy Text Block] Equity Method Investment, Underlying Equity in Net Assets Equity method investment, underlying equity in net assets Collaborative Arrangement Collaborative Arrangement [Member] Stock Purchase Agreement Stock Purchase Agreement [Member] Stock purchase agreement [Member]. Entity Address, Address Line Two Entity Address, Address Line Two Fair Value Measurements Fair Value Disclosures [Text Block] Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Conversion of preferred shares to common stock Shares Conversion of preferred shares to common stock Shares Plan Name [Domain] Milestone Two Milestone Two [Member] Milestone Two Member. Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Entity Entity [Domain] Maximum percentage of common stock ownership together with affiliates allowable after exercise of prefunded warrants Maximum Percentage Of Common Stock Ownership Together With Affiliates Allowable After Exercise Of Prefunded Warrants Maximum percentage of common stock ownership together with affiliates allowable after exercise of prefunded warrants. Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Milestone payments Stock price appreciation milestone payment (in millions) Milestone Payments Milestone payments during the period. Entity Address, City or Town Entity Address, City or Town Convertible Preferred Stock And Stockholders Deficit Disclosure [Abstract] Convertible preferred stock and stockholders' equity. Security Exchange Name Security Exchange Name Ono Pharmaceutical Company Ltd [Member] Ono Pharmaceutical Company Ltd. Ono Pharmaceutical Company Ltd Counterparty Name Counterparty Name [Axis] Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Restructuring And Related Cost Number Of Positions Retained Restructuring And Related Cost Number Of Positions Retained Restructuring and related cost number of positions retained. Statistical Measurement Statistical Measurement [Domain] Exercise price of warrants Class of Warrant or Right, Exercise Price of Warrants or Rights Assets, Current Total current assets Total stock-based compensation expense Stock-based compensation Share-Based Payment Arrangement, Expense Document Period End Date Document Period End Date Title of Individual Title and Position [Axis] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Net Rentable Area Collaborative arrangement annual payments receivable recorded as deferred revenue Non-refundable upfront payments recorded as deferred revenue Collaborative Arrangements Upfront Payments Recorded Under Deferred Revenue Represents the amount of upfront payments received under collaborative arrangements is recorded as deferred revenue. Accrued payroll and other employee benefits Accrued Salaries, Current CIRM award liability current. C I R M Award Liability Current CIRM award liability, current portion Statement of Financial Position [Abstract] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Pre-funded warrants Pre-funded warrants Pre-funded warrants Revenue Recognition Revenue [Policy Text Block] Conversion price Preferred Stock Conversion Price Preferred stock conversion price. Antidilutive Security, Excluded EPS Calculation [Table] Class of Stock Class of Stock [Axis] Tenant Improvements Tenant Improvements Financial Instruments Financial Instruments [Domain] Ft Eight Thirty Six [Member] Ft Eight Thirty Six [Member] FT836 [Member] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Two Maximum percentage of common stock ownership after change upon notice Maximum Percentage Of Common Stock Ownership After Change Upon Notice Maximum percentage of common stock ownership after change upon notice. Redmile Group, LLC and Affiliates Redmile Group Limited Liability Company And Affiliates [Member] Redmile Group, LLC and Affiliates. Prepaid Expenses And Other Assets Prepaid Expenses And Other Assets [Member] Prepaid expenses and other assets. Weighted-average common shares used to compute diluted net loss per share Weighted Average Number of Shares Outstanding, Diluted Weighted Average Number of Shares Outstanding, Diluted, Total Entity File Number Securities Act File Number OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Unrealized loss on investments California Institute for Regenerative Medicine Award Award Agreement For Research And Development Disclosure [Text Block] Award agreement for research and development disclosure. Pre-Funded Warrants Pre Funded Warrants [Member] Pre-Funded Warrants. Cover [Abstract] Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Cancelled Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Stock price appreciation milestones Stock Price Appreciation Milestones [Member] Stock price appreciation milestone. Treasuries, Non-U.S. Government Securities, Municipal Securities, Corporate Debt Securities and Commercial Paper U.S. Treasury debt securities US Treasury Securities [Member] Number of Operating Segments Number Of Operating Segments Sale of Stock Sale of Stock [Domain] Segment Reporting Segment Reporting Disclosure [Text Block] General and Administrative Expense, Total General and administrative General and Administrative Expense Upfront fee. Upfront Fee Upfront Fee [Member] Percentage of reduction on milestone payments Collaborative Arrangement Percentage Of Reduction On Milestone Payments Collaborative arrangement percentage of reduction on milestone payments. Short-term Debt, Type Short-Term Debt, Type [Domain] Short-term Debt, Type Short-Term Debt, Type [Axis] Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of Future Minimum Payments Under Non-cancelable Operating Leases Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Funding Support the Conduct of Pre_ Clinical and Investigational New Drug (IND) Funding Support the Conduct of Pre_ Clinical and Investigational New Drug Funding Support the Conduct of Pre_ Clinical and Investigational New Drug Contract with Customer, Liability, Current Deferred revenue Conversion of preferred shares to common stock Stock Issued During Period, Shares, Conversion of Convertible Securities Unrecognized compensation cost related to unvested restricted shares Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Investment Holdings, Schedule of Investments [Table Text Block] Aggregated by investment category and the length of time Lease term Lessee, Operating Lease, Term of Contract Research Activities, Expense Research Activities, Expense Research activities Organization and Summary of Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Long-term Investments, Total Long-term investments Long-Term Investments Common Stock, Shares, Outstanding, Ending Balance Common Stock, Shares, Outstanding, Beginning Balance Common stock, outstanding shares Common Stock, Shares, Outstanding Operating lease liabilities, current portion Operating Lease, Liability, Current Collaboration agreement Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Depreciation, Depletion and Amortization, Total Depreciation and amortization Depreciation, Depletion and Amortization Schedule of Determine the Estimated Fair Value of the Stock Price Appreciation Milestones Payments Schedule Of Milestone Payments Valuation Assumptions Table [Text Block] Schedule of milestone payments valuation assumptions table text block. Document Transition Report Document Transition Report Short-Term Investments Short-Term Investments, Total Short-term investments Total operating expenses Operating Expenses Current accrued expenses Accrued Liabilities, Current [Abstract] Research and Development Expense, Total Research and development Research and Development Expense Award From Regenerative Medicine Institute [Table] Award From Regenerative Medicine Institute [Table] Award from regenerative medicine institute. Leases Lessee, Operating Leases [Text Block] Class A Convertible Preferred Stock Convertible Preferred Stock [Member] Convertible Preferred Stock Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Statement of Cash Flows [Abstract] Weighted-Average Grant Date Fair Value per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Aggregate purchase price of common stock Public offering of common stock, net of issuance costs Stock Issued During Period, Value, New Issues Financial assets: Assets, Fair Value Disclosure [Abstract] Convertible Preferred Stock and Stockholders’ Equity Equity [Text Block] Convertible preferred stock Temporary Equity [Line Items] Shares, Issued Ending Balance (in shares) Beginning Balance (in shares) Profits and losses sharing percentage Profit Loss Sharing Percentage Profit loss sharing percentage. Non-U.S. government securities Debt Security, Government, Non-US [Member] Summary of Restricted Stock Unit Activity Under The Plan Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Net loss Net loss Net loss Stock price appreciation milestone, income StockPriceAppreciationMilestoneIncome StockPriceAppreciationMilestoneIncome Other Nonoperating Income Other income Other income Total operating lease expense Operating Lease, Cost Cash Provided by (Used in) Operating Activity, Continuing Operation Cash Provided by (Used in) Operating Activity, Continuing Operation, Total Cash flows from operations Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Assets Assets [Abstract] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Increase (Decrease) in Prepaid Expense and Other Assets, Total Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Common stock of public offering and issuance of pre funded warrants. Common Stock Of Public Offering And Issuance Of Pre Funded Warrants Public offering of common stock and issuance of pre-funded warrants, net of issuance costs(in shares) Document Fiscal Year Focus Document Fiscal Year Focus Stock Price Appreciation Milestone Payable Stock price appreciation milestone payable Stock price appreciation milestone payable. Facilities Costs Facilities Costs Facilities costs Investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Milestone One Milestone One [Member] Milestone one member. Accounts Payable, Current, Total Accounts payable Accounts Payable, Current Research and Development Expense [Member] Research and Development Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Deferred Revenue, Total Deferred revenue Deferred Revenue Enterprise value milestones liability at fair value Enterprise Value Milestones Liability At Fair Value Enterprise Value Milestones Liability At Fair Value. Conversion of preferred shares to common stock Value Conversion of preferred shares to common stock Value Issuance of common stock from equity incentive plans, net of issuance costs Proceeds from Stock Options Exercised Fair Value Disclosures [Abstract] 2027 Lessee, Operating Lease, Liability, to be Paid, Year One Net proceeds from issuance of shares after related cash costs Sale of Stock, Consideration Received on Transaction Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Share-Based Payment Arrangement [Abstract] Total financial assets measured at fair value on a recurring basis Financial assets/ Non-financial assets Assets, Fair Value Disclosure Sale of Stock [Axis] Sale of Stock Stock Purchase Agreement Stock Purchase Agreement [Axis] Stock purchase agreement axis. Award From Regenerative Medicine Institute [Abstract] Award from regenerative medicine institute. Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Net cash provided by investing activities Title of 12(b) Security Title of 12(b) Security Cancelled Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Cancelled Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Money market funds Money Market Funds [Member] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Remaining 2026 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Legal Entity Legal Entity [Axis] Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Letters of credit outstanding amount Letters of Credit Outstanding, Amount Balance at the beginning of the period Balance at the end of the period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Equity premium per share Equity Premium On Share Price Per Share Under Agreement Equity premium on share price per share under agreement. Additional Paid In Capital Additional Paid-in Capital [Member] Company Received Payment Company Received Payment Company received payment Measurement Frequency Measurement Frequency [Domain] Income Statement Location Statement of Income Location, Balance [Axis] Trading Symbol Trading Symbol Other segment expenses Other Segment Expenses Other Segment Expenses Public offering of common stock and issuance of pre-funded warrants, net of issuance costs Public offering of common stock and issuance of pre-funded warrants. Public Offering Of Common Stock And Issuance Of Pre Funded Warrants Financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Fair Value Measurements Recurring Fair Value, Recurring [Member] Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Entity Ex Transition Period Entity Ex Transition Period Total undiscounted lease payments Future minimum payments under the operating leases Lessee, Operating Lease, Liability, to be Paid Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Candidate 1 Candidate One [Member] Candidate one. Stock price appreciation milestones Stock Price Appreciation Milestones Stock price appreciation milestones. Aggregate equity premium on shares Aggregate Equity Premium On Shares Issued Under Agreement Aggregate equity premium on shares issued under agreement. Equity Components Equity Components [Axis] Equity Component Equity Component [Domain] Asset Class Asset Class [Axis] Percentage of tax credit Percentage of Tax Credit Percentage of Tax Credit Sublicense Consideration Sublicense Consideration [Member] Sublicense consideration. Collaborative Arrangements Collaborative Arrangement, Accounting Policy [Policy Text Block] Maximum Maximum [Member] Liabilities, Fair Value Disclosure, Total Total financial liabilities measured at fair value on a recurring basis Liabilities, Fair Value Disclosure Statistical Measurement Statistical Measurement [Axis] Exercised Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Common stock, $0.001 par value; authorized shares - 350,000,000; issued and outstanding - 116,272,513 at March 31, 2026 and 115,359,735 at December 31, 2025 Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Total Common Stock, Value, Issued Principles of Consolidation Consolidation, Policy [Policy Text Block] Rule 10b51 Arr Modified Flag Rule 10b51 Arr Modified Flag Rule 10b5-1 Arrangement Modified Schedule of Other Nonoperating Income, by Component [Table Text Block] Schedule of sublease Income Wages per employee Payments to Employees Percentage of common stock ownership upon preferred stock conversion Percentage Of Common Stock Ownership Upon Preferred Stock Conversion Percentage of common stock ownership upon preferred stock conversion. Corresponding Asset For Sublicense Consideration Paid Sublicense consideration paid Corresponding asset for sublicense consideration paid. Enterprise value milestone payment Enterprise Value Milestone Payment Enterprise value milestone payment. Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Preferred stock, shares authorized Preferred Stock, Shares Authorized Costs and Expenses Costs and Expenses Costs and Expenses, Total Research and development fees cash payments received Proceeds From Research And Development Fees Received Proceeds From Research and Development Fees Received. Finite-Lived Intangible Assets by Major Class Finite-Lived Intangible Assets by Major Class [Axis] Award From California Institute For Regenerative Medicine [Abstract] Award from the california institute for regenerative medicine. Award From California Institute For Regenerative Medicine Abstract Entity Registrant Name Entity Registrant Name Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Unrealized Losses Summary of all Possible Stock Price Appreciation Milestone Payments Common Stock Multiples And The Enterprise Value Milestone Payments Table [Text Block] Common stock multiples and the enterprise value milestone payments. Total other income Other Nonoperating Income (Expense) Income expense in change in fair value of the stock price appreciation milestones Total other income Candidate 3 Candidate Three [Member] Candidate Three [Member] Additional Paid in Capital, Ending Balance Additional Paid in Capital, Beginning Balance Additional Paid in Capital, Total Additional paid-in capital Additional Paid in Capital Award for first-in-human clinical trial Award For First In Human Clinical Trial Award for first-in-human clinical trial. Measurement Frequency Measurement Frequency [Axis] cash-related expenses cash-related expenses Employee Retention Credit Employee Retention Credit [Member] Employee Retention Credit [Member] Proceeds from Issuance of Common Stock Public offering of common stock, net of issuance costs Other comprehensive loss: Other Comprehensive Income (Loss), Tax [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Refundable tax credit Refundable Tax Credit Refundable Tax Credit Liability Class [Axis] Liability Class Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income (loss) Payments to Acquire Property, Plant, and Equipment, Total Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Restrictions on Cash and Cash Equivalents [Table Text Block] Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash Temporary Equity By Class Of Stock [Table] Temporary Equity, by Class of Stock [Table] Total assets Assets Income Statement [Abstract] Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Stock Purchase Agreement Stock Purchase Agreement [Domain] Stock purchase agreement domain. First Disbursement Amount Under The Award Payable For Next Twelve Months First Disbursement Amount Under The Award Payable For Next Twelve Months First Disbursement Amount Under The Award Payable For Next Twelve Months Award from California institute for regenerative medicine Award From Regenerative Medicine Institute [Line Items] Award from regenerative medicine institute. Issuance of common stock in conjunction with public offering (in shares) Stock Issued During Period, Shares, New Issues Public offering of common stock, net of issuance costs (in shares) Lease, Cost [Abstract] Vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Earnings Per Share, Diluted Earnings Per Share, Diluted, Total Net loss per common share, diluted Net loss per share, diluted Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of segment profit or loss, including segment expenses Grant award. Grant Award Grant awarded Title of Individual Title and Position [Domain] City Area Code City Area Code First Disbursement Amount Under The Award First Disbursement Amount Under The Award First Disbursement Amount Under The Award The Premises 2020 Lease Agreement Lease Agreements [Member] Risk-free interest rate Fair Value Assumptions Risk Free Interest Rate1 Fair Value Assumptions Risk Free Interest Rate 1. Upfront Fee and Equity Premium Upfront Fee And Equity Premium [Member] Upfront fee and equity premium. Counterparty Name Counterparty Name [Domain] Convertible preferred stock. Convertible Preferred Stock Policy [Text Block] Convertible Preferred Stock Change in fair value of stock price appreciation milestones Change in fair value of stock price appreciation milestones Increase Decrease In Fair Value Of Stock Price Appreciation Milestones Increase decrease in fair value of stock price appreciation milestones. Variable lease expense Variable Lease, Cost Clinical development milestone fees Clinical Development Milestone Fees Clinical Development Milestone Fees Remaining weighted-average lease term Operating Lease, Weighted Average Remaining Lease Term Segment Reporting Information [Line Items] Issuance of common stock upon vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Letter of Credit Letter of Credit [Member] Investments [Abstract] Property, Plant and Equipment, Net, Ending Balance Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Total Property and equipment, net Property, Plant and Equipment, Net Issuance of common stock during period for private placements (in shares) Stock Issued During Period Shares For Private Placement Stock issued during period shares for private placement Total cash, cash equivalents, and restricted cash shown in the unaudited condensed consolidated statement of cash flows Cash, cash equivalents and restricted cash at beginning of the period Cash, cash equivalents and restricted cash at end of the period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Loss from operations Operating Income (Loss) Preferred shares converted into common stock percentage of ownership change upon notice Percentage Of Common Stock Ownership For Preferred Stock Conversion Change Upon Notice Percentage of common stock ownership for preferred stock conversion change upon notice. Accumulated Deficit Retained Earnings [Member] Cash and Cash Equivalents Cash and Cash Equivalents [Axis] Costs related to equity offering Payments of Stock Issuance Costs Liabilities, Noncurrent Liabilities, Noncurrent, Total Non-Current Liability Liquidity and Capital Resources Liquidity and Capital Resources [Policy Text Block] Liquidity and Capital Resources [Policy Text Block] Proceeds From Collaboration Partner Proceeds From Collaboration Partner Proceeds from collaboration partner Operating lease liabilities, weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Operating lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Quoted prices in Active Market for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Preclinical and Investigational New Drug (IND), Award Granted Preclinical and Investigational New Drug (IND), Award Granted Preclinical and Investigational New Drug (IND), Award Granted Class Of Stock [Line Items] Class of Stock [Line Items] Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Net cash provided by financing activities Schedule of Components of Lease Expense Lease, Cost [Table Text Block] Aggregate milestone payments Collaborative Arrangement Aggregate Milestone Payments Receivable Collaborative arrangement aggregate milestone payments receivable. Nonoperating Income (Expense) [Abstract] Other income (expense): Other Long-Term Investments [Member] Long-term Investments Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Anti-Dilutive Securities not Included in Calculation of Net Loss per Common Share Corporate debt securities Corporate Debt Securities [Member] Debt Securities, Available-for-Sale [Table] Entity Interactive Data Current Entity Interactive Data Current Deferred revenue Deferred revenue Increase (Decrease) in Contract with Customer, Liability Income Statement Location Statement of Income Location, Balance [Domain] Total Amount Disbursed Under The Award Total Amount Disbursed Under The Award Total amount disbursed under the award Operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Number of shares to be issued upon conversion Convertible Preferred Stock, Shares Issued upon Conversion Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table] Proceeds from Related Party Debt Proceeds from related party Accretion and amortization of premiums and discounts on investments, net Accretion and amortization of premiums and discounts on investments, net Accretion (Amortization) of Discounts and Premiums, Investments Entity Tax Identification Number Entity Tax Identification Number Share Price Closing stock price as of remeasurement date Straight-line lease expense Straight Line Rent Adjustments Amended Mskcc License Amended MSKCC License [Member] Amended MSKCC License [Member] FT516 F T Five One Six [Member] FT516. Summary of Stock Option Activity and Related Information Under All Equity Plans Schedule of Stock Options Roll Forward [Table Text Block] Local Phone Number Local Phone Number Related Party Transaction Related Party Transaction [Domain] Unrecognized compensation cost related to outstanding options Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Short-Term Lease, Cost Total short-term lease expense Non-Voting Class A Preferred Stock Preferred Class A [Member] Collaboration contract assets Collaboration contract asset Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent, Total Accrued issuance costs included in additional paid-in-capital Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Revenue from Contract with Customer, Excluding Assessed Tax, Total Revenue recognized Collaboration revenue Revenue from Contract with Customer, Excluding Assessed Tax Net Income (Loss) Attributable to Parent [Abstract] Numerator: 2030 Lessee, Operating Lease, Liability, to be Paid, Year Four Class of Stock Class of Stock [Domain] Commercial Paper Commercial Paper [Member] Commercial paper Expected recognition weighted average period of unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Cash, Cash Equivalents, and Short-Term Investments Cash, Cash Equivalents, and Short-Term Investments, Total Cash equivalents and short-term investments Schedule Of Stock By Class [Table] Stock, Class of Stock [Table] Entity Emerging Growth Company Entity Emerging Growth Company Collaborative arrangement potential additional milestones Collaborative Arrangement Potential Additional Milestones Collaborative arrangement potential additional milestones.